Table 5 Valganciclovir and herpesvirus reactivation. Data is given as number (%)
|  | LT recipients (n = 71) |  | |
|---|---|---|---|
|  | Valganciclovir prophylaxis (n = 34) | No Valganciclovir prophylaxis (n = 37) | p |
EBV positive | 3/34 (8.9%) | 9/37 (24.3%) | 0.07 |
CMV positive | 3/33 (9.1%) | 10/36 (27.8%) | 0.04 |
HHV-6 positive | 13/34 (38.2%) | 10/37 (27%) | 0.25 |
HHV-7 positive | 6/34 (17.6%) | 7/37 (18.9%) | 0.9 |